3-氨基-3-环己基丙酸

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 3-氨基-3-环己基丙酸
• 英文名称: 3-amino-3-cyclohexylpropanoic acid
• 英文别名: 3-azaniumyl-3-cyclohexylpropanoate
• 化学式: C₉H₁₇NO₂
• 分子量: 171.239
• InChiKey: XGRSAFKZAGGXJV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-氨基-3-环己基丙酸 在 氯化亚砜 、 三乙胺 作用下， 以 甲苯 、 苯 为溶剂， 反应 2.0h， 生成 Ethyl 3-cyclohexyl-3-isocyanatopropanoate
  参考文献：
  名称：

  Organosilicon synthesis of isocyanates: III. Synthesis of aliphatic, carbocyclic, aromatic, and alkylaromatic isocyanatocatboxylic acid esters

  摘要：

  A series of aminoacid esters was prepared by treating the aminoacid suspensions in ethanol with thionyl chloride. Best conversion of aminoacid esters to corresponding isocyanates was achieved in the case of aromatic and carbocyclic aminoesters by phosgeneation of their N-silyl derivatives, and in the case of aliphatic and alkylaromatic aminoesters by phosgeneation of O-silyl or N,O-bissilylurethanes on their basis. In the last case additional step of esterification of the by-products isocyanatoalkylcarboxylic acid chlorides is reqired after phosgeneation. Unusual generation of cynnamates and intramolecular N -> O-migration of trimethylsilyl group in the solutions of silylated alkylaromatic beta-aminoacid esters were found.

  DOI：

  10.1134/s1070363206070115
• 作为产物：
  描述：

  环己烷基甲醛 在 氨 作用下， 生成 3-氨基-3-环己基丙酸
  参考文献：
  名称：

  Rodionow; Kiselewa, Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya, 1952, p. 278,282

  摘要：

  DOI：

文献信息

• SUBSTITUTED HETEROCYCLIC COMPOUNDS
  申请人：ZHUO Jincong

  公开号：US20100240671A1

  公开（公告）日：2010-09-23

  The present invention relates to substituted heterocyclic compounds of Formula I or XI: or pharmaceutically acceptable salts or N-oxides or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are histamine II4 receptor inhibitors useful in the treatment of histamine II4 receptor-associated conditions or diseases or disorders including, for example, inflammatory diseases or disorders, pruritus, and pain.

  本发明涉及式I或XI的取代杂环化合物： 或其药用可接受的盐或N-氧化物或季铵盐，其中所述成员在此提供，并且它们的组合物和使用方法，这些方法是组胺H24受体抑制剂，用于治疗组胺H24受体相关的疾病或疾病，包括例如炎症性疾病或疾病，瘙痒和疼痛。
• [EN] NEW ANTIBACTERIAL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS ANTIBACTÉRIENS
  申请人：ACRAF

  公开号：WO2016096631A1

  公开（公告）日：2016-06-23

  The present invention relates to novel antibacterial compounds, pharmaceutical compositions containing them and their use as antimicrobials.

  本发明涉及新型的抗菌化合物、含有它们的药物组合物以及它们作为抗菌剂的应用。
• Design, Synthesis, and Testing of Potent, Selective Hepsin Inhibitors via Application of an Automated Closed-Loop Optimization Platform
  作者：Shishir M. Pant、Amanda Mukonoweshuro、Bimbisar Desai、Manoj K. Ramjee、Christopher N. Selway、Gary J. Tarver、Adrian G. Wright、Kristian Birchall、Timothy M. Chapman、Topi A. Tervonen、Juha Klefström

  DOI：10.1021/acs.jmedchem.7b01698

  日期：2018.5.24

  role in hepatocyte growth factor (HGF) signaling and epithelial integrity makes it a target of therapeutic interest in carcinogenesis and metastasis. Using an integrated design, synthesis, and screening platform, we were able to rapidly develop potent and selective inhibitors of hepsin. In progressing from the initial hit 7 to compound 53, the IC50 value against hepsin was improved from ∼1 μM to 22

  肝素是一种膜锚定的丝氨酸蛋白酶，其在肝细胞生长因子（HGF）信号传导和上皮完整性中的作用使其成为癌变和转移的治疗靶标。使用集成的设计，合成和筛选平台，我们能够快速开发出有效的和选择性的肝素抑制剂。从最初的命中7到化合物53的过程中，针对肝素的IC 50值从约1μM提高到22 nM，并且对尿激酶型纤溶酶原激活剂（uPA）的选择性从30倍增加至> 6000倍。随后的体外ADMET分析和细胞研究证实，领先的化合物是用于研究肝素在乳腺肿瘤发生中的作用的有用工具。
• [EN] 2-CYANOPYRROLES AND THEIR ANALOGUES AS DDP-IV INHIBITORS<br/>[FR] 2-CYANOPYRROLES ET LEURS ANALOGUES EN TANT QU'INHIBITEURS DE DIPEPTIDYLPEPTIDASE-IV (DP-IV)
  申请人：NOVO NORDISK AS

  公开号：WO2004089362A1

  公开（公告）日：2004-10-21

  The present invention relates to therapeutically active and selective inhibitors of the enzyme DPP-IV having the formula I: (I) The invention furthermore relates to pharmaceutical compositions comprising the compounds and the use of such compounds for the manufacture of medicaments for treating diseases that are associated with proteins which are subject to inactivation by DPP-IV, such as type 2 diabetes and obesity.

  本发明涉及具有以下式I的治疗活性和选择性抑制剂的酶DPP-IV。此外，本发明还涉及包含这些化合物的药物组合物，以及利用这些化合物制造用于治疗与DPP-IV使蛋白质失活相关的疾病的药物，例如2型糖尿病和肥胖症。
• COMPOUNDS FOR ALZHEIMER'S DISEASE
  申请人：Slade Rachel

  公开号：US20080249135A1

  公开（公告）日：2008-10-09

  The invention provides novel compounds useful for the treatment of neurodegenerative disorders including Alzheimer's disease and dementia. The compounds have a substituents chosen from -L-C(═O)OH, -L-CH═CHC(═O)OH, -L-C(═O)NH 2 , -L-C(═O)NH(C 1-3 alkyl), -L-C(═O)N(C 1-3 alkyl) 2 , -L-S(═O) 2 (C 1-3 alkyl), -L-S(═O) 2 NH 2 , -L-S(═O) 2 N(C 1-3 alkyl) 2 , -L-S(═O) 2 NH(C 1-3 alkyl), -L-C(═O)NHOH, -L-C(═O)CH 2 NH 2 , -L-C(═O)CH 2 OH, -L-C(═O)CH 2 SH, -L-C(═O)NHCN, -L-NHC(═O)OR o , -L-C(═O)NHR o , -L-NH(C═O)NHR o , -L-C(═O)N(R o ) 2 , -L-NH(C═O)N(R o ) 2 , -L-sulfo, -L-(2,6 difluorophenol), -L-phosphono, and -L-tetrazolyl, where L is a linker.

  这项发明提供了用于治疗神经退行性疾病，包括阿尔茨海默病和痴呆症的新型化合物。这些化合物具有从-L-C(═O)OH，-L-CH═CHC(═O)OH，-L-C(═O)NH2，-L-C(═O)NH(C1-3烷基)，-L-C(═O)N(C1-3烷基)2，-L-S(═O)2(C1-3烷基)，-L-S(═O)2NH2，-L-S(═O)2N(C1-3烷基)2，-L-S(═O)2NH(C1-3烷基)，-L-C(═O)NHOH，-L-C(═O)CH2NH2，-L-C(═O)CH2OH，-L-C(═O)CH2SH，-L-C(═O)NHCN，-L-NHC(═O)ORo，-L-C(═O)NHRo，-L-NH(C═O)NHRo，-L-C(═O)N(Ro)2，-L-NH(C═O)N(Ro)2，-L-sulfo，-L-(2,6二氟苯酚)，-L-磷酸酯和-L-四唑基的取代基中选择，其中L是连接物。